BCEL Stock: Atreca, Inc. Stock Price, Analysis & Insights
Get live bcel stock price $0.09, comprehensive Atreca, Inc. stock analysis, charts, news, and expert forecast. Real-time bcel stock data and investment insights.
Loading chart...
Company Overview
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. Atreca, Inc. was incorporated in 2010 and is based in San Carlos, California.
Company Information
- CEO
- John A. Orwin
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 90
Contact Information
- Website
- https://www.atreca.com
- Address
- 835 Industrial Road
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
Business Model & Strategy
Atreca, Inc. operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO John A. Orwin, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Atreca, Inc. competes in the Biotechnology within the broader Healthcare. With 3.6 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Global Select, Atreca, Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Atreca, Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Atreca, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Atreca, Inc.
- ⚠Investors should consider how Atreca, Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
3.57M
P/E Ratio
-0.04
Beta
1.03
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 3.57M market capitalization
- Trading Volume: 122.11K shares traded today
- Price Range: 52-week range of $0.05 - $1.20
- Exchange: Listed on NASDAQ Global Select
Financial Metrics
Market Analysis for Atreca, Inc.
Atreca, Inc. (BCEL) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 3.57M, the company represents a significant player in its market. The stock is currently trading at $0.09 with a negativedaily change of 1.32%.
The company's 90 employee base and presence on the NASDAQ Global Selectexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -0.04, beta of 1.03, and 52-week price range from $0.05 to $1.20when evaluating investment opportunities.
Why Invest in Atreca, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Select)
- • Experienced leadership under John A. Orwin
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.